Brief: Valbiotis Announces Positive Results In Bioavailability And Mode Of Action Totum•854 Clinical Study

Valbiotis SA

30/01/2023 16:48

Jan 30 (Reuters) - Valbiotis SA  ALVAL.PA :
    * VALBIOTIS ANNOUNCES POSITIVE RESULTS IN THE
BIOAVAILABILITY AND
MODE OF ACTION TOTUM•854 CLINICAL STUDY, AGAINST HIGH BLOOD
PRESSURE
    * TOTUM•854 ALSO REDUCES ANGIOTENSIN I-CONVERTING ENZYME
(ACE1)
ACTIVITY, ONE OF MAIN MODES OF ACTION KNOWN TO REDUCE BLOOD
PRESSURE
    * STUDY RESULTS CONFIRM POTENTIAL OF TOTUM•854 AGAINST MILD
TO
MODERATE HIGH BLOOD PRESSURE IN HUMANS
    * TOTUM•854 PROTECTS HUMAN CELLS OF VASCULAR WALL,
PARTICULARLY
AGAINST INFLAMMATION AND OXIDATIVE STRESS, WHICH IS KEY TO
PREVENTING WORSENING OF HIGH BLOOD PRESSURE
    * WITH A VIEW TO MARKETING TOTUM•854, VALBIOTIS IS TARGETING
SIGNATURE OF INTERNATIONAL PARTNERSHIPS AND WILL MARKET DIRECTLY
ON FRENCH MARKET

Source text for Eikon:  ID:nBw6T17sTa 
Further company coverage:  ALVAL.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))